{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"groups":[{"description":"Cycle 1- 5-azacytidine (Vidaza, AZA) 75mg/m2 IV/SC daily on days 1-7.\n\nSubsequent Cycles (cycles to be repeated every 28 days) AZA 75mg/m2 IV/SC daily on days 1-7.","id":"OG000","title":"5-azacytidine and Lintuzumab"}],"populationDescription":"No participants were analyzed due to withdrawal of the investigational agent by the company.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Explore the Biologic Role of microRNAs in Determining Clinical Response to the AZA Plus Lintuzumab Combination and Achievement of the Other Pharmacodynamic Endpoints","type":"SECONDARY"}